Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention

June 13th 2025

Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.

Dr Sonpavde on Nivolumab Plus Ipilimumab in Untreated Unresectable/Metastatic Urothelial Carcinoma

June 12th 2025

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Dr Jankowski on the Telomere-Targeted Agent THIO With Cemiplimab in Advanced NSCLC

June 12th 2025

Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.

New EBMT Machine Learning Model Outperforms Available Tools in Predicting Transplant Risk in Myelofibrosis

June 12th 2025

The EBMT have developed a machine learning model designed to identify and stratify transplant risk for patients with myelofibrosis.

Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma

June 11th 2025

Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.

Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC

June 11th 2025

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

Phase 1 Data Pave the Way for Further Investigation of IMA203 in Advanced Melanoma

June 11th 2025

Jason J. Luke, MD, FACP, discusses data for the PRAME-targeted TCR T-cell therapy IMA203 in advanced or metastatic melanoma.

The Role of Liquid Biopsies in Precision Approaches for Breast Cancer Therapy

June 11th 2025

Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.

RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer

June 10th 2025

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

T-DXd Plus Pertuzumab Displays Significant PFS Benefit Over SOC Therapy in Frontline HER2+ Advanced Breast Cancer

June 10th 2025

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Dr Kalinsky on Efficacy Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses data with camizestrant plus a CDK4/6 inhibitor in ER–positive, HER2-negative advanced breast cancer.

China’s Center for Drug Evaluation Accepts MAA for Pimicotinib in TGCT

June 10th 2025

The Center for Drug Evaluation of the Chinese NMPA has accepted the marketing authorization application for pimicotinib in patients with TGCT.

First-Line Lurbinectedin Plus Atezolizumab Maintenance Under Priority Review for ES-SCLC

June 10th 2025

The FDA granted priority review to the sNDA seeking the approval of the first-line maintenance combination of lurbinectedin and atezolizumab for ES-SCLC.

ABLE-32 Looks to Expand the Use of Nadofaragene Firadenovec Into Intermediate-Risk NMIBC

June 10th 2025

A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.

Real-World Data Help Fill the Gaps Left by Clinical Trial Results in Urothelial Carcinoma

June 9th 2025

David J. Benjamin, MD, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.

Dr Rugo on QOL Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 9th 2025

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Pirtobrutinib Adds Effective Option to CLL Treatment Landscape, Underscoring Treatment Selection Considerations

June 6th 2025

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Dr Mayer on ESR1 Testing Methods in the SERENA-6 Study of Patients With ER+/HER2– Advanced Breast Cancer

June 5th 2025

Erica L. Mayer, MD, MPH, discusses ESR1 mutation detection by ctDNA liquid biopsy in the phase 3 SERENA-6 study.

China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer

June 5th 2025

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

China’s NMPA Accepts NDA for Sintilimab Plus Fruquintinib in Second-Line Advanced/Metastatic RCC

June 5th 2025

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA